Open AccessNilotinib therapy after resistance to imatinib
Author(s) -
Raffaele Porrini,
E Madon
Publication year - 2015
Publication title -
clinical management issues
Language(s) - English
Resource type - Journals
eISSN - 2283-3137
pISSN - 1973-4832
DOI - 10.7175/cmi.v6i2s.1137
Subject(s) - nilotinib , medicine , imatinib , tyrosine kinase inhibitor , myeloid leukemia , tyrosine kinase , pharmacology , chronic myeloid leukaemia , oncology , receptor , cancer
In this article we present the case of a 43-year-old man with chronic myeloid leukemia (CML) successfully treated with nilotinib. At presentation we started him on imatinib at standard dose of 400 mg/day but after 36 months of treatment the patient didn’t achieve a molecular response. We switched him on second-generation tyrosine kinase inhibitor (TKI), nilotinib, at the dose of 800 mg/day. After twelve months on nilotinib the patient obtained a complete molecular response. During treatment with nilotinib we did not observe any drug-related toxicity.